ACUTE PAIN IN RHEUMATOLOGIST’S PRACTICE

Cover Page

Cite item

Full Text

Abstract

Acute pain is one of the most frequent reasons for patients’ presentation that significantly decreases quality of life and results in disability. It is important to notice that analgesic therapy effectiveness becomes the most important criteria of treatment quality for the patient. Successful analgesic therapy allows to increase treatment compliance and to improve communication between the medical practitioner and the patient. At the same time not significant acute pain control may become a reason for its chronification. Among prognostic factors of acute pain chronification special mention should go to baseline pain high intensity, insufficient treatment effectiveness, catastrophizing of the condition by the patient, psychological disorders (depression, anxiety) as well as physical labor and excess body mass. As inflammation is one of the main mechanisms of acute and chronic pain development, non-steroid anti-inflammatory drugs (NSAIDs) should be considered as a first line analgesic therapy. The use of NSAIDs in rheumatology is indicated as a symptomatic analgesic and anti-inflammatory medication in acute and chronic musculoskeletal pain in patients with musculoskeletal system disorders (osteoarthritis, rheumatoid arthritis, and spondylarthritis), non-specific back pain, metabolic arthropathies, local soft tissue inflammation of rheumatologic genesis (tendinitis, tendovaginitis, bursitis), also in treatment of ankylosing spondylitis NSAIDs are the main group of pathogenic medication that allows to slow disease progression. In intensive acute pain treatment where timing of analgesic effect onset is principal, the use of intravenous and intramuscular NSAIDs injections is justified. For effective help to the patients with pain syndrome it is necessary to choose a NSAIDs medication with significant therapeutic effect, rapid effect development and good safety profile. Dexketoprofen (Dexalgin®) has all these qualities. The article describes data from Russian and foreign studies where Dexketoprofen (Dexalgin®) was shown to be effective as an analgesic and anti-inflammatory therapy in many disorders associated with musculoskeletal pain. Its doubtless advantages include significant analgesic effect, rapidity of therapeutic effect, availability of dosage forms for parenteral (intramuscular and intravenous) use, and solid experience of use

About the authors

Elena lu. Pogozheva

Nasonova Research Institute of Rheumatology

Email: dr.pogozheva@gmail.com
канд. мед. наук, науч. сотр. ФГБНУ «НИИР им. В.А. Насоновой» Москва, Россия

Vera N. Amirdzhanova

Nasonova Research Institute of Rheumatology

д-р мед. наук, вед. науч. сотр. ФГБНУ «НИИР им. В.А. Насоновой» Москва, Россия

Andrei E. Karateev

Nasonova Research Institute of Rheumatology

д-р мед. наук, рук. лаб. патофизиологии боли и полиморфизма скелетно-мышечных заболеваний ФГБНУ «НИИР им В.А. Насоновой» Москва, Россия

References

  1. Kahlenberg CA, Nwachukwu BU, McLawhorn AS et al. Patient satisfaction after total knee replacement: a systematic review. HSS J 2018; 14 (2): 192-201.
  2. Chua JR, Gibson KA, Pincus T Pain and other self-report scores in patients with osteoarthritis indicate generally similar disease burden to patients with rheumatoid arthritis. Clin Exp Rheumatol 2017; 35 (Suppl. 107); 5: 88-93.
  3. Ten Klooster PM, Veehof MM, Taal E et al. Changes in priorities for improvement in patients with rheumatoid arthritis during 1 year of anti-tumour necrosis factor treatment. Ann Rheum Dis 2007; 66 (11): 1485-90.
  4. Althaus A, Arranz Becker O, Moser KH et al. Postoperative pain trajectories and pain chronifica-tion-an empirical typology of pain patients. Pain Med 2018; 19 (12): 2536-45.
  5. Gilron I, Vandenkerkhof E, Katz J et al. Evaluating the association between acute and chronic pain after surgery: impact of pain measurement methods. Clin J Pain 2017; 33 (7): 588-94.
  6. Blichfeldt-Eckhardt MR. From acute to chronic postsurgical pain: the significance of the acute pain response. Dan Med J 2018; 65 (3). ID B5326.
  7. Blichfeldt-Eckhardt MR, Andersen C, Ording H et al. From acute to chronic pain after thoracic surgery: the significance of different components of the acute pain response. J Pain Res 2018; 11: 1541-8.
  8. Lewis GN, Rice DA, McNair PJ, Kluger M. Predictors of persistent pain after total knee arthroplasty: a systematic review and meta-analysis. Br J Anaesth 2015; 114 (4): 551-61.
  9. Beneciuk JM, Lentz TA, He Y et al. Prediction of persistent musculoskeletal pain at 12 months: a secondary analysis of the optimal screening for prediction of referral and outcome (OSPRO) Validation Cohort Study. Phys Ther 2018; 98 (5): 290-301.
  10. Gerhart JI, Burns JW, Bruehl S et al. Variability in negative emotions among individuals with chronic low back pain: relationships with pain and function. Pain 2018; 159 (2): 342-50.
  11. Lagersted-Olsen J, Bay H, Jorgensen MB et al. Low back pain patterns over one year among 842 workers in the DPhacto study and predictors for chronicity based on repetitive measurements. BMC Musculoskelet Disord 2016; 17 (1). ID 453.
  12. Friedman BW, Gensler S Yoon A et al. Predicting threemonth functional outcomes after an ED visit for acute low back pain. Am J Emerg Med 2017; 35 (2): 299-305.
  13. Clark J, Nijs J, Yeowell G, Goodwin PC. What are the predictors of altered central pain modulation in chronic musculoskeletal pain populations? A systematic review. Pain Physician 2017; 20 (6): 487-500.
  14. Каратеев А.Е., Насонов Е.Л., Яхно Н.Н. и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Соврем. ревматология. 2015; 9 (1): 4-24. [Karateev A.E., Nasonov E.L., Iakhno N.N. et al. Klinicheskie rekomendatsii "Ratsional'noe prime-nenie nesteroidnykh protivovospalitel'nykh preparatov (NPVP) v klinicheskoi praktike'. Sovrem. revmatologiia. 2015; 9 (1): 4-24 (in Russian).]
  15. Клинические рекомендации. Ревматология. Под ред. Е.Л.Насонова. М.: ГЭОТАР-Медиа, 2017; с. 349-55. [Clinical recommendations. Rheumatology. Pod red. E.L.Nasonova. Moscow: GEOTAR-Media, 2017; p. 349-55 (in Russian).] ИНФОРМАЦИЯ ОБ АВТОРАХ / INFORMATION ABOUT THE AUTHORS
  16. Henry D, Lim L, Garcia Rodriguez L et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312: 1563-6.
  17. Lanas A, Garsia-Rodriguez L, Arroyo M et al. Risk of upper gastrointestinal ulcer bleeding associated with selective COX-2 inhibitors, traditional non-steroidal non-aspirin NSAID, aspirin, and combinations. Gut published online 10 may 2006; doi: 10.1136/gut.2005.080754.
  18. Barbanoj M, Antonijoan R, Gich I. Clinical pharmacokinetics of dexketoprofen. Clin Pharmacokinet 2001; 40 (4): 245-62.
  19. Rodriguez MJ, Arbos RM, Amaro SR. Dexketoprofen trometamol: clinical evidence supporting its role as a painkiller. Exp Rev Neurother 2008; 8 (11): 1625-40. doi: 10.1586/14737175.8.11.1625
  20. Walczak JS. Analgesic properties of dexketoprofen trometamol. Pain Manag 2011; 1 (5): 409-16. doi: 10.2217/pmt.11.42
  21. Iohom G, Walsh M, Higgins G, Shorten G. Effect of perioperative administration of dexketoprofen on opioid requirements and inflammatory response following elective hip arthroplasty. Br J Anaesth 2002; 88 (4): 520-6.
  22. Торшин И.Ю., Громова О.А., Федотова Л.Э., Громов А.Н. Сравнительный хемореактомный анализ декскетопрофена, кетопрофена и диклофенака. Неврология, нейропсихиатрия, психосоматика. 2018; 10 (1): 47-54. [Torshin I.Iu., Gromova O.A., Fedotova L.E., Gromov A.N. Sravnitel'nyi khemoreaktomnyi analiz deksketoprofena, ketoprofena i diklofenaka. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2018; 10 (1): 47-54 (in Russian).]
  23. Moore RA, Barden J. Systematic review of dexketoprofen in acute and chronic pain. BMC Clin Pharmacol 2008; 8: 11. doi: 10.1186/1472-6904-8-11
  24. Metscher B, Kubler U, Jahnel-Kracht H. Dexketoprofen-trometamol and tramadol in acute lumbago. Fortschr Med Orig 2001; 118 (4): 147-51.
  25. Zippel H, Wagenitz A. A multicentre, randomised, double-blind study comparing the efficacy and tolerability of intramuscular dexketoprofen versus diclofenac in the symptomatic treatment of acute low back pain. Clin Drug Invest 2007; 27 (8): 533-43.
  26. Eken C, Serinken M, Elicabuk H et al. Intravenous paracetamol versus dexketoprofen versus morphine in acute mechanical low back pain in the emergency department: a randomised doubleblind controlled trial. Emerg Med J 2014; 31 (3): 177-81. doi: 10.1136/emermed-2012-201670
  27. Tunali Y, Akpil EF, Dilmen OK et al. Efficacy of intravenous paracetamol and dexketoprofen on postoperative pain and morphine consumption after a lumbar disk surgery. J Neurosurg Anesthesiol 2013; 25 (2): 143-7. doi: 10.1097/ANA.0b013e31827464.
  28. Demirozogul E, Yilmaz A, Ozen M et al. Intravenous dexketoprofen versus paracetamol in non-traumatic musculoskeletal pain in the emergency department: A randomized clinical trial. Am J Emerg Med 2019. pii: S0735-6757(19)30045-2. doi: 10.1016/j.ajem.2019.01.040
  29. Zippel H, Wagenitz A. Comparison of the efficacy and safety of intravenously administered dexketoprofen trometamol and ketoprofen in the management of pain after orthopaedic surgery: A multicentre, double-blind, randomised, parallel-group clinical trial. Clin Drug Invest 2006; 26 (9): 517-28.
  30. Sjovall S, Kokki M, Nokela A et al. Intravenous dexketoprofen induces less injection pain than racemic ketoprofen. J Clin Pharm Ther 2015; 40 (4): 431-5. doi: 10.1111/jcpt.12284
  31. Sivrikoz N, Koltka K, Guresti E et al. Perioperative dexketoprofen or lornoxicam administration for pain management after major orthopedic surgery: a randomized, controlled study. Agri 2014; 26 (1): 23-8. doi: 10.5505/agri.2014.09821
  32. Подчуфарова Е.В. Дексалгин в лечении острых болевых синдромов пояснично-крестцовой локализации. Боль.2005; 2: 41-4. [Podchufarova E.V. Deksalgin v lechenii ostrykh bolevykh sindromov poiasnichno-kresttsovoi loka-lizatsii. Bol'. 2005; 2: 41-4 (in Russian).]
  33. Чичасова Н.В. Новые подходы к купированию острого болевого синдрома в ревматологии и неврологии. Consilium Medicum. 2009; 11 (2):50-5. [Chichasova N.V. Novye podkhody k kupirovaniiu ostrogo bolevogo sindroma v revmatologii i nev-rologii. Consilium Medicum. 2009; 11 (2):50-5 (in Russian).]
  34. Барулин А.Е., Курушина О.В. Комплексная терапия острой и хронической боли в спине с применением препарата дексалгин. Журн. неврологии и психиатрии им. C.C. Корсакова. 2012; 112 (11): 61-4. [Barulin A.E., Kurushina O.V. Kompleksnaia terapiia ostroi i khronicheskoi boli v spine s primeneni-em preparata deksalgin. Zhurn. nevrologii i psikhiatrii im. C.C. Korsakova. 2012; 112 (11): 61-4 (in Russian).]
  35. Carne X, Rios J, Torres F Postmarketing cohort study to assess the safety profile of oral dexketoprofen trometamol for mild to moderate acute pain treatment in primary care. Methods Find Exp Clin Pharmacol 2009; 31 (8): 533-40.
  36. Laporte J, Ibanez L, Vidal X et al. Upper gastrointestinal bleeding associated with the use of NSAIDs. Drug Saf 2004; 27 (6): 411-20.

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies